Cognizin is a branded form of Citicoline, a natural chemical found in every cell of the body. Citicoline provides an essential nutrient for cells — particularly brain cells.

Cognizin supports brain health in several ways. First, brain imaging technology has shown that Cognizin helps increase brain energy. Second, Cognizin provides essential structural components for synthesizing brain cell membranes, which may help facilitate brain cell communication. And third, Cognizin helps support the formation of several brain chemicals that regulate cognitive function.*

Cognizin has been the subject of several human clinical trials. The most recent trial studied the effect of Cognizin on healthy middle aged adults. Using the latest brain scanning technology, researchers at the Harvard-associated Brain Imaging Center at McLean Hospital observed increases in brain activity among people who had taken Cognizin for six weeks, particularly when they performed tasks that required sustained attention or memory.

• Clinical and laboratory research indicates that Cognizin Citicoline supports memory function and healthy cognition.*

• Some clinical evidence suggests that citicoline may improve mild memory problems associated with normal aging.*

• Citicoline is a water-soluble compound essential for the synthesis of phosphatidylcholine, a major constituent of brain tissue.*

• Citicoline enhances communication between neurons in the brain to support visual function and protect neural structures from free radical damage.*

• Citicoline supports brain performance by enhancing metabolism and healthy brain activity.*

• Citicoline assists in sustaining the health of mitochondria in the brain, the energy factories inside the brain cells.*

• Citicoline supports healthy brain metabolism by nourishing and maintaining phospholipds in brain cells.*

• Citicoline supports the activity of nerves in the brain that respond to acetylcholine.*

• Citicoline helps maintain normal levels of acetylcholine, an important brain chemical that regulates memory and cognitive function.*

• Citicoline may support cognitive function. Citicoline facilitates healthy brain cell communication.*

• Research evidence suggests that citicoline may help maintain healthy memory and thinking ability.*

• Research evidence suggests that citicoline may support healthy brain cell and cognitive function.*

• Citicoline helps brain cells communicate by keeping cell membranes in good condition.*

• Citicoline supports energy in brain cells.*

Cognizin can be used as a food ingredient in the United States for use at levels of 250 mg. per serving in various food products, beverages and beverage bases, breakfast cereals, chewing gum, dairy product analogs, frozen dairy desserts, grain products and pastas, hard candies, milk and milk products, processed fruits and fruit juices, and soft candy.

Clinical research has found that Cognizin increases levels of ATP — the body’s main energy storage molecule — in brain cells, thus enhancing brain energy.* That’s significant, because while the brain makes up only 2 percent of the body’s weight, it consumes 20 percent of the body’s energy. The more efficiently brain cells can produce energy, the more effectively the brain functions as a whole.

Because Cognizin helps make more energy available to brain cells, they are better able to perform their daily tasks. Cells membranes are synthesized and maintained. Vital brain chemicals are produced. Electrical impulses are generated. These activities help improve the overall functioning of the brain, which is why Cognizin helps to significantly increase the ability to focus, concentrate, and make decisions.*

Research suggests the minimum effective dose of Cognizin is 500 mg. per day.

• Food and Nutrition Board, Institute of Medicine. Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline. National Academy Press, Washington DC, 1998.

• Wurtman RJ et al. Effect of oral CDP-choline on plasma choline and uridine levels in humans. Biochem Pharmacol. 2000;60(7):989-92.

• Rao AM et al. CDP-choline: neuroprotection in transient forebrain ischemia of gerbils. J Neurosci Res. 1999;58(5):697-705.

• Secades JJ, Lorenzo JL. CDP-choline: pharmacological and clinical review, 2006 update. Meth Find Exp Clin Pharmacol. 2006;27(Suppl B):1-56.

• Silveri MM et al. Citicoline enhances frontal lobe bioenergetics as measured by phosphorus magnetic resonance spectroscopy. NMR Biomed. 2008; www.interscience.wiley.com DOI:10.1002/nbm.1281.

• Lopez-Coviella I et al. Evidence that 5'-cytidinediphospho- choline can affect brain phospholipid composition by increasing choline and cytidine plasma levels. J Neurochem. 1995;65(2):889-94.

• Babb SM et al. Chronic citicoline increases phosphodiesters in the brains of healthy older subjects: an in vivo phosphorus magnetic resonance spectroscopy study. Psychopharmacology (Berl). 2002;161:248-54.

• Conant R, Schauss AG. Therapeutic applications of citicoline for stroke and cognitive dysfunction in the elderly: a review of the literature. Alt Med Rev. 2004;9:1, 17-31.

• Dixon CE et al. Effects of CDP-choline treatment on neurobehavioral deficits after TBI and on hippocampal and neocortical acetylcholine release. J Neurotrauma. 1997;14:161-69.

• Fiorvanti M, Yanagi M. Citidinediphosphocholine (CDP choline) for cognitive and behavioral disturbances associated with chronic cerebral disorders in the elderly (Cochrane Review). In: The Cochrane Library, Oxford, England: Update Software: 2002:4.

• Spiers PA et al. Citicoline improves verbal memory in aging. Arch Neurol. 996;53:441-48.

• Alvarez XA et al. Citicoline improves memory performance in elderly subjects. Meth Find Exp Clin Pharmacol. 1997;19(3):201-10.

• Clark WM et al. A randomized doseresponse trial of citicoline in acute ischemic stroke patients. Neurology. 1997;49:671-78.

• Davalos A et al. Oral citicoline in acute ischemic stroke: An individual patient data pooling analysis of clinical trials. Stroke. 2002;33:2850-57.

For more information visit www.cognizin.com

Cognizin is a trademark of Kyowa Hakko Bio Co. Ltd.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended diagnose, treat, cure or prevent any disease.